Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Nanobiotix S.A. - ADSs (NQ:NBTX)

22.20 +0.92 (+4.32%)
Delayed Quote Updated: 3:11 PM EDT, Oct 15, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Nanobiotix S.A. - ADSs

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
News headline image
Earnings Scheduled For April 24, 2023 ↗
Companies Reporting Before The Bell • Dynex Cap (NYSE:DX) is estimated to report quarterly earnings at $0.17 per share on revenue of $6.99 million. 
Via Benzinga
News headline image
NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix to Postpone Full Year 2022 Financial Results and Conference Call
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) 
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) 
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix Posts Updated Data For Radiotherapy-Activated Cancer Therapy In Head & Neck Cancer Patients ↗
 
Via Benzinga
News headline image
NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer
Data to be discussed during Nanobiotix Q3 Earnings Call at 8:00AM EST 
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Voting Rights and Shares Capital of the Company
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3
Multidisciplinary board includes twelve (12) experts from the United States and Europe that will support the development of lead therapeutic candidate NBTXR3 
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Present at the Jefferies London Healthcare Conference
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022
Conference Call and Webcast to be Held at 8:00 AM ET / 2:00 PM CET on November 10, 2022 
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
NANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank
From Nanobiotix S.A.
Via GlobeNewswire
News headline image
Nanobiotix: Voting Rights and Shares Capital of the Company
From Nanobiotix
Via Business Wire
News headline image
Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022
From Nanobiotix
Via Business Wire
News headline image
Earnings Scheduled For September 28, 2022 ↗
Companies Reporting Before The Bell • Lilium (NASDAQ:LILM) is expected to report earnings for its second quarter. 
Via Benzinga
News headline image
Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022
From Nanobiotix
Via Business Wire
News headline image
Nanobiotix Establishes Recommended Dose For Registrational Study Of Head & Neck Combo Therapy Trial ↗
Nanobiotix (NASDAQ: NBTX) determined the recommended phase 2 dose (RP2D) of the NBTXR3 combo regime for inoperable locoregional recurrent or recurrent and metastatic head and neck squamous cell... 
Via Benzinga
News headline image
Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy
From Nanobiotix
Via Business Wire
News headline image
Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024
From Nanobiotix
Via Business Wire
News headline image
Nanobiotix: Voting Rights and Shares Capital of the Company
From Nanobiotix
Via Business Wire
News headline image
12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗
  
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
Good morning! It's time for another overview of the biggest pre-market stock movers as we see what's happening on Thursday! 
Via InvestorPlace
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.